Abstract |
Kinase cascades are involved in all stages of tumorigenesis through modulation of transformation and differentiation, cell-cycle progression, and motility. Advances in molecular targeted drug development allow the design and synthesis of inhibitors targeting cancer-associated signal transduction pathways. Potent selective inhibitors with low toxicity can benefit patients especially with several malignancies harboring an oncogenic driver addictive signal. This article evaluates information on solid tumor-related kinase signals and inhibitors, including receptor tyrosine kinase or serine/threonine kinase signals that lead to successful application in clinical settings. In addition, the resistant mechanisms to the inhibitors is summarized.
|
Authors | Yosuke Togashi, Kazuto Nishio |
Journal | Nihon rinsho. Japanese journal of clinical medicine
(Nihon Rinsho)
Vol. 73
Issue 8
Pg. 1323-9
(Aug 2015)
ISSN: 0047-1852 [Print] Japan |
PMID | 26281685
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- Benzamides
- Biomarkers, Tumor
- Indoles
- Phenylurea Compounds
- Piperazines
- Protein Kinase Inhibitors
- Pyrazoles
- Pyridines
- Pyrimidines
- Quinazolines
- Sulfonamides
- Vemurafenib
- Niacinamide
- Crizotinib
- Imatinib Mesylate
- Sorafenib
- Protein Kinases
- EGFR protein, human
- ErbB Receptors
- Trastuzumab
- Gefitinib
|
Topics |
- Antibodies, Monoclonal, Humanized
- Benzamides
- Biomarkers, Tumor
(analysis)
- Crizotinib
- Drug Discovery
- Drug Resistance, Neoplasm
- ErbB Receptors
- Gefitinib
- Humans
- Imatinib Mesylate
- Indoles
- Molecular Targeted Therapy
- Neoplasms
(diagnosis, drug therapy, enzymology, genetics)
- Niacinamide
(analogs & derivatives)
- Phenylurea Compounds
- Piperazines
- Protein Kinase Inhibitors
(pharmacology, therapeutic use)
- Protein Kinases
(physiology)
- Pyrazoles
- Pyridines
- Pyrimidines
- Quinazolines
- Signal Transduction
(drug effects, genetics)
- Sorafenib
- Sulfonamides
- Trastuzumab
- Vemurafenib
|